Cannabinoid technology "Sol-Gel"

In our country, technologies have been developed for the delivery of non-drug cannabinoids to the human body using cosmetic preparations, patches, or using vaginal / rectal suppositories, excluding their entry into the stomach or intestines.

The UniQuest (UQ) commercialization division of the University of Queensland has granted the Canadian company the rights to use intranasal cannabinoid delivery technology.

The technology, dubbed “Sol-Gel,” was developed by Dr. Harendra Pareh of UQ School of Pharmacy and his team. “Sol-Gel” is a liquid solution at room temperature that becomes a gel upon contact with the higher temperature of the human body. Designed for use in intranasal drug delivery scenarios that allow better absorption of cannabinoids through nasal mucosal adhesion.

 Dr. Harendra Pareh (second from left) and research team examining the module 

Nasal delivery bypasses the stomach and intestines, eliminating first-pass metabolism - potentially improving bioavailability. The gel format means the cannabinoids can be released more slowly than a conventional nasal spray system - up to seven days. The sustained release delivery system can be used for a number of indications: pain, inflammation, seizures, and neurological disorders.

According to Steven Van Deventer, Chairman and CEO of PreveCeutical, “With this licensing agreement, we can work with partners to commercialize products containing the cannabinoid Sol-Gel in a nasal spray.” In addition to the nasal spray, PreveCeutical is also exploring other product formats for delivering cannabinoids, including through the skin. 

Commentary of the specialists of the Association "Ukrainian technical hemp"

Canadian health and wellness company PreveCeutical has been working with UniQuest to develop the Sol-Gel system since 2017. I would like to note that in our country, technologies have been developed for the delivery of non-drug cannabinoids into the human body using cosmetic preparations, patches or using vaginal / rectal suppositories, excluding their entry into the stomach or intestines. To our deepest regret, these methods are provided to foreign companies for implementation due to the fact that the use of cannabinoids of plant origin in our country is currently not sufficiently regulated.